Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats

Molecular Medicine Reports

Volumn 11, Issue 3, 2015, Pages 1685-1692

  Huang, Kun ^a   Kang, Xiaowen ^a   Wang, Xinyan ^a   Wu, Shijie ^b   Xiao, Jinling ^a   Li, Zhaoguo ^a   Wu, Xiaomei ^a   Zhang, Wei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b DAQING OILFIELD CO LTD   (China)

Author keywords

Bone marrow mesenchymal stem cells; Oxidative stress; Pulmonary fibrosis; Type II alveolar epithelial cells

Indexed keywords

BLEOMYCIN; SUPEROXIDE DISMUTASE; SURFACTANT PROTEIN C; AQUAPORIN 5; MESSENGER RNA;

ADHERENT CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW BIOPSY; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; LUNG ALVEOLUS; LUNG ALVEOLUS EPITHELIUM; LUNG BLOOD VESSEL; LUNG FIBROSIS; LUNG PARENCHYMA; MACROPHAGE; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; TYPE II ALVEOLAR EPITHELIAL CELL; Y CHROMOSOME; ANIMAL; CELL TRANSDIFFERENTIATION; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION; GENETICS; LUNG ALVEOLUS CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; AQUAPORIN 5; CELL TRANSDIFFERENTIATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; OXIDATIVE STRESS; PNEUMOCYTES; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; RATS; RNA, MESSENGER;

EID: 84916608624     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2981     Document Type: Article

References (45)

1. Fernandez IE and Eickelberg O: New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380: 680-688, 2012.
2. Crestani B, Marchand-Adam S, Fabre A, Dehoux M and Soler P: Mechanisms in pulmonary fibrosis. Rev Prat 57: 2222-2226, 2007 (In French).
3. Nuovo GJ, Hagood JS, Magro CM, et al: The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol 25: 416-433, 2012.
4. Starosta V, Ratjen F, Rietschel E, Paul K and Griese M: Anti-inflammatory cytokines in cystic fibrosis lung disease. Eur Respir J 28: 581-587, 2006.
5. Simonian PL, Roark CL, Born WK, O'Brien RL and Fontenot AP: Gammadelta T cells and Th17 cytokines in hypersensitivity pneumonitis and lung fibrosis. Transl Res 154: 222-227, 2009.
6. Tan HL, Regamey N, Brown S, et al: The Th17 pathway in cystic fibrosis lung disease. Am J Respir Crit Care Med 184: 252-258, 2011.
7. Okada M, Suzuki K, Matsumoto M, et al: Effects of angiotensin on the expression of fibrosis-associated cytokines, growth factors, and matrix proteins in human lung fibroblasts. J Clin Pharm Ther 34: 288-299, 2009.
8. Ruan W and Ying K: Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis? Pathol Res Pract 206: 537-543, 2010.
9. Datta A, Scotton CJ and Chambers RC: Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol 163: 141-172, 2011.
10. Maher TM: Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 33: 69-83, 2012.
11. Sisson TH, Mendez M, Choi K, et al: Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 181: 254-263, 2010.
12. Kliment CR and Oury TD: Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med 49: 707-717, 2010.
13. El-Khouly D, El-Bakly WM, Awad AS, El-Mesallamy HO and El-Demerdash E: Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats. Toxicology 302: 106-113, 2012.
14. Cheresh P, Kim SJ, Tulasiram S and Kamp DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta 1832: 1028-1040, 2012.
15. Lu TH, Chen CH, Lee MJ, et al: Methylmercury chloride induces alveolar type II epithelial cell damage through an oxidative stress-related mitochondrial cell death pathway. Toxicol Lett 194: 70-78, 2010.
16. Shi C: Recent progress toward understanding the physiological function of bone marrow mesenchymal stem cells. Immunology 136: 133-138, 2012.
17. Charbord P: Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther 21: 1045-1056, 2010.
18. Daba MH, El-Tahir KE, Al-Arifi MN and Gubara OA: Drug-induced pulmonary fibrosis. Saudi Med J 25: 700-706, 2004.
19. Kan I, Melamed E and Offen D: Integral therapeutic potential of bone marrow mesenchymal stem cells. Curr Drug Targets 6: 31-41, 2005.
20. Jiang Y, Jahagirdar BN, Reinhardt RL, et al: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418: 41-49, 2002.
21. Kotton DN, Ma BY, Cardoso WV, et al: Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development 128: 5181-5188, 2001.
22. Ortiz LA, Gambelli F, McBride C, et al: Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100: 8407-8411, 2003.
23. Mora AL and Rojas M: Aging and lung injury repair: a role for bone marrow derived mesenchymal stem cells. J Cell Biochem 105: 641-647, 2008.
24. Li HP, Li X, He GJ, Yi XH and Kaplan AP: The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats. Respirology 9: 25-32, 2004.
25. Padilla-Nash HM, Barenboim-Stapleton L, Difilippantonio MJ and Ried T: Spectral karyotyping analysis of human and mouse chromosomes. Nat Protoc 1: 3129-3142, 2006.
26. Zhao F, Zhang YF, Liu YG, et al: Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 40: 1700-1705, 2008.
27. Feng SW, Yao XL, Li Z, et al: In vitro bromodeoxyuridine labeling of rat bone marrow-derived mesenchymal stem cells. Di Yi Jun Yi Da Xue Xue Bao 25: 184-186, 2005 (In Chinese).
28. Dominici M, Le Blanc K, Mueller I, et al: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-317, 2006.
29. Li X, Zhang Y and Qi G: Evaluation of isolation methods and culture conditions for rat bone marrow mesenchymal stem cells. Cytotechnology 65: 323-334, 2013.
30. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW and Crystal RG: Bleomycin induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 120: 893-899, 1979.
31. Tanaka K, Ishihara T, Azuma A, et al: Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 298: L348-L360, 2010.
32. Narahara M, Yamada A, Hamada-Kanazawa M, Kawai Y and Miyake M: cDNA cloning of the Sry-related gene Sox6 from rat with tissue-specific expression. Biol Pharm Bull 25: 705-709, 2002.
33. Liu J, Wang X, Wang F, Teng L and Cao J: Attenuation effects of heparin-superoxide dismutase conjugate on bleomycin-induced lung fibrosis in vivo and radiation-induced inflammatory cytokine expression in vitro. Biomed Pharmacother 63: 484-491, 2009.
34. Wei X, Liu H, Sun X, et al: Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci Lett 386: 58-62, 2005.
35. Qi HP, Wei SQ, Gao XC, et al: Ursodeoxycholic acid prevents selenite-induced oxidative stress and alleviates cataract formation: In vitro and in vivo studies. Mol Vis 18: 151-160, 2012.
36. Bowden DH: Unraveling pulmonary fibrosis: the bleomycin model. Lab Invest 50: 487-488, 1984.
37. Wang D, Haviland DL, Burns AR, Zsigmond E and Wetsel RA: A pure population of lung alveolar epithelial type II cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 104: 4449-4454, 2007.
38. Wang D, Morales JE, Calame DG, Alcorn JL and Wetsel RA: Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther 18: 625-634, 2010.
39. Kapanci Y, Weibel ER, Kaplan HP and Robinson FR: Pathogenesis and reversibility of the pulmonary lesions of oxygen toxicity in monkeys. II. Ultrastructural and morphometric studies. Lab Invest 20: 101-118, 1969.
40. Castranova V, Rabovsky J, Tucker JH and Miles PR: The alveolar type II epithelial cell: a multifunctional pneumocyte. Toxicol Appl Pharmacol 93: 472-483, 1988.
41. Fehrenbach H: Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2: 33-46, 2001.
42. Emura M, Ochiai A, Singh G, et al: In vitro reconstitution of human respiratory epithelium. In Vitro Cell Dev Biol Anim 33: 602-605, 1997.
43. Jiang Y, Jahagirdar BN, Reinhardt RL, et al: Pluripoteney of mesenehymal stem cells derived from adult marrow. Nature 418: 41-49, 2002.
44. Ablin RJ: The need for personalized therapy and companion diagnostics in prostate cancer. Biomark Med 5: 281-283, 2011.
45. Caspary WJ, Lanzo DA and Niziak C: Effect of deoxyribonucleic acid on the production of reduced oxygen by bleomycin and iron. Biochemistry 21: 334-338, 1982.